Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis
- PDF / 1,301,041 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 62 Downloads / 209 Views
Cancer Cell International Open Access
REVIEW
Prognostic value of systemic immune‑inflammation index in patients with urologic cancers: a meta‑analysis Yilong Huang1,2, Yunfeng Gao3, Yushen Wu4* and Huapeng Lin5*
Abstract Background: Several studies have reported that the systemic immune-inflammation index (SII) is associated with the prognosis of patients with urologic cancers (UCs). The aim of this study was to systematically evaluate the prognostic value of SII in UC patients. Methods: We searched public databases for relevant published studies on the prognostic value of SII in UC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled to assess the relationships between SII and overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), overall response rate (ORR) and disease control rate (DCR). Results: A total of 14 studies with 3074 patients were included. From the pooled results, we found that high SII was associated with worse overall survival (OS) in patients with UC (HR 2.58, 95% CI 1.59–4.21). Patients with high SII values also had poorer PFS (HR 1.92, 95% CI 1.29–2.88) and CSS (HR 2.58, 95% CI 1.36–4.91) as well as lower ORRs (HR 0.40, 95% CI 0.22–0.71) than patients with low SII values. In addition, the subgroup analysis of OS and PFS showed that the prognosis of patients with high SII was worse than that of patients with low SII. Conclusions: SII might be a promising noninvasive predictor in patients with UC. However, more samples and multicenter studies are needed to confirm the effectiveness of SII in predicting the prognosis of patients with UC. Keywords: Urologic cancer, Meta-analysis, Prognosis, Systemic immune-inflammation index (SII) Background Urologic cancer is a group of cancers that occur in the urinary system. The incidence of urologic cancer is still high. Kidney cancer is the seventh most common malignancy in men and the ninth most common malignancy in women globally [1]. Bladder cancer is the fourth and eleventh most common cancer among men and women *Correspondence: [email protected]; [email protected] 4 Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing 400042, People’s Republic of China 5 Department of Intensive Care Unit, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, 261 Huansha Road, Hangzhou 310006, Zhejiang, People’s Republic of China Full list of author information is available at the end of the article
worldwide [2]. Prostate cancer is the most common type of cancer in men and the second leading cause of cancerrelated death in men [2]. Despite advances in the early diagnosis and treatment of urologic cancers, the prognosis remains poor due to local recurrence or distal metastasis [3, 4]. Therefore, noninvasive detection tools such as serum biomarkers are increasingly valued for their simplicity and predictive value. Inflammation is an important predi
Data Loading...
